Restoration of CAPAN-1 cells with functional BRCA2 provides insight into the DNA repair activity of individuals who are heterozygous for BRCA2 mutations

Cancer Genetics and Cytogenetics

Volumn 186, Issue 2, 2008, Pages 85-94

  Holt, Jeffrey T ^a   Toole, William P ^b   Patel, Vedang R ^b   Hwang, HeeYoung ^b   Brown, Erika T ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; DOUBLE STRANDED DNA; RAD51 PROTEIN;

ALLELE; ARTICLE; BREAST CANCER; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN INTERACTION;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; GENES, BRCA2; HELA CELLS; HUMANS; MUTATION; NUCLEAR LOCALIZATION SIGNALS; PANCREATIC NEOPLASMS; RAD51 RECOMBINASE;

EID: 53449096415     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.06.013     Document Type: Article

References (50)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
2. Sharan S.K., Morimatsu M., Albrecht U., Lim D.S., Regel E., Dinh C., Sands A., Eichele G., Hasty P., and Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386 (1997) 804-810
3. Yuan S.S., Lee S.Y., Chen G., Song M., Tomlinson G.E., and Lee E.Y. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 59 (1999) 3547-3551
4. Ogawa T., Yu X., Shinohara A., and Egelman E.H. Similarity of the yeast RAD51 filament to the bacterial RecA filament. Science 259 (1993) 1896-1899
5. Benson F.E., Stasiak A., and West S.C. Purification and characterization of the human Rad51 protein, an analogue of E. coli RecA. EMBO J 13 (1994) 5764-5771
6. Derbyshire M.K., Epstein L.H., Young C.S., Munz P.L., and Fishel R. Nonhomologous recombination in human cells. Mol Cell Biol 14 (1994) 156-169
7. Jackson S.P., and Jeggo P.A. DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. Trends Biochem Sci 20 (1995) 412-415
8. Roth D.B., Porter T.N., and Wilson J.H. Mechanisms of nonhomologous recombination in mammalian cells. Mol Cell Biol 5 (1985) 2599-2607
9. Roth D.B., and Wilson J.H. Nonhomologous recombination in mammalian cells: role for short sequence homologies in the joining reaction. Mol Cell Biol 6 (1986) 4295-4304
10. Takata M., Sasaki M.S., Sonoda E., Morrison C., Hashimoto M., Utsumi H., Yamaguchi-Iwai Y., Shinohara A., and Takeda S. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 17 (1998) 5497-5508
11. Johnson R.D., and Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J 19 (2000) 3398-3407
12. Taki T., Ohnishi T., Yamamoto A., Hiraga S., Arita N., Izumoto S., Hayakawa T., and Morita T. Antisense inhibition of the RAD51 enhances radiosensitivity. Biochem Biophys Res Commun 223 (1996) 434-438
13. Sonoda E., Sasaki M.S., Buerstedde J.M., Bezzubova O., Shinohara A., Ogawa H., Takata M., Yamaguchi-Iwai Y., and Takeda S. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 17 (1998) 598-608
14. Tsuzuki T., Fujii Y., Sakumi K., Tominaga Y., Nakao K., Sekiguchi M., Matsushiro A., Yoshimura Y., and Morita T. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci U S A 93 (1996) 6236-6240
15. Mizuta R., LaSalle J.M., Cheng H.L., Shinohara A., Ogawa H., Copeland N., Jenkins N.A., Lalande M., and Alt F.W. RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. Proc Natl Acad Sci U S A 94 (1997) 6927-6932
16. Wong A.K., Pero R., Ormonde P.A., Tavtigian S.V., and Bartel P.L. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 272 (1997) 31941-31944
17. Chen P.L., Chen C.F., Chen Y., Xiao J., Sharp Z.D., and Lee W.H. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 95 (1998) 5287-5292
18. Marmorstein L.Y., Ouchi T., and Aaronson S.A. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A 95 (1998) 13869-13874
19. Aihara H., Ito Y., Kurumizaka H., Yokoyama S., and Shibata T. The N-terminal domain of the human Rad51 protein binds DNA: structure and a DNA binding surface as revealed by NMR. J Mol Biol 290 (1999) 495-504
20. Matsuo Y., Sakane I., Takizawa Y., Takahashi M., and Kurumizaka H. Roles of the human Rad51 L1 and L2 loops in DNA binding. FEBS J 273 (2006) 3148-3159
21. Bignell G., Micklem G., Stratton M.R., Ashworth A., and Wooster R. The BRC repeats are conserved in mammalian BRCA2 proteins. Hum Mol Genet 6 (1997) 53-58
22. Spain B.H., Larson C.J., Shihabuddin L.S., Gage F.H., and Verma I.M. Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci U S A 96 (1999) 13920-13925
23. Davies A.A., Masson J.Y., McIlwraith M.J., Stasiak A.Z., Stasiak A., Venkitaraman A.R., and West S.C. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7 (2001) 273-282
24. Stark J.M., Pierce A.J., Oh J., Pastink A., and Jasin M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol 24 (2004) 9305-9316
25. Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L., and Venkitaraman A.R. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420 (2002) 287-293
26. Shin D.S., Pellegrini L., Daniels D.S., Yelent B., Craig L., Bates D., Yu D.S., Shivji M.K., Hitomi C., Arvai A.S., Volkmann N., Tsuruta H., Blundell T.L., Venkitaraman A.R., and Tainer J.A. Full-length archaeal Rad51 structure and mutants: mechanisms for RAD51 assembly and control by BRCA2. EMBO J 22 (2003) 4566-4576
27. Yu V.P., Koehler M., Steinlein C., Schmid M., Hanakahi L.A., van Gool A.J., West S.C., and Venkitaraman A.R. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 14 (2000) 1400-1406
28. Yang H., Jeffrey P.D., Miller J., Kinnucan E., Sun Y., Thoma N.H., Zheng N., Chen P.L., Lee W.H., and Pavletich N.P. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297 (2002) 1837-1848
29. Yano K., Morotomi K., Saito H., Kato M., Matsuo F., and Miki Y. Nuclear localization signals of the BRCA2 protein. Biochem Biophys Res Commun 270 (2000) 171-175
30. Boulikas T. Nuclear import of DNA repair proteins. Anticancer Res 17 (1997) 843-863
31. Arnold K., Kim M.K., Frerk K., Edler L., Savelyeva L., Schmezer P., and Wiedemeyer R. Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair. Cancer Lett 243 (2006) 90-100
32. Goggins M., Schutte M., Lu J., Moskaluk C.A., Weinstein C.L., Petersen G.M., Yeo C.J., Jackson C.E., Lynch H.T., Hruban R.H., and Kern S.E. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56 (1996) 5360-5364
33. Ozcelik H., Schmocker B., Di Nicola N., Shi X.H., Langer B., Moore M., Taylor B.R., Narod S.A., Darlington G., Andrulis I.L., Gallinger S., and Redston M. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16 (1997) 17-18
34. Oddoux C., Struewing J.P., Clayton C.M., Neuhausen S., Brody L.C., Kaback M., Haas B., Norton L., Borgen P., Jhanwar S., Goldgar D., Ostrer H., and Offit K. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14 (1996) 188-190
35. Neuhausen S., Gilewski T., Norton L., Tran T., McGuire P., Swensen J., Hampel H., Borgen P., Brown K., Skolnick M., Shattuck-Eidens D., Jhanwar S., Goldgar D., and Offit K. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 13 (1996) 126-128
36. Roa B.B., Boyd A.A., Volcik K., and Richards C.S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14 (1996) 185-187
37. Abeliovich D., Kaduri L., Lerer I., Weinberg N., Amir G., Sagi M., Zlotogora J., Heching N., and Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60 (1997) 505-514
38. Levy-Lahad E., Catane R., Eisenberg S., Kaufman B., Hornreich G., Lishinsky E., Shohat M., Weber B.L., Beller U., Lahad A., and Halle D. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60 (1997) 1059-1067
39. Yoneda Y., Semba T., Kaneda Y., Noble R.L., Matsuoka Y., Kurihara T., Okada Y., and Imamoto N. A long synthetic peptide containing a nuclear localization signal and its flanking sequences of SV40 T-antigen directs the transport of IgM into the nucleus efficiently. Exp Cell Res 201 (1992) 313-320
40. -455-A polymorphism. Blood 92 (1998) 3286-3293
41. Hao C.M., Redha R., Morrow J., and Breyer M.D. Peroxisome proliferator-activated receptor δ activation promotes cell survival following hypertonic stress. J Biol Chem 277 (2002) 21341-21345
42. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., and Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273 (1998) 5858-5868
43. Rogakou E.P., Boon C., Redon C., and Bonner W.M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 146 (1999) 905-916
44. Morimatsu M., Donoho G., and Hasty P. Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to γ-radiation and premature senescence. Cancer Res 58 (1998) 3441-3447
45. Abbott D.W., Freeman M.L., and Holt J.T. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90 (1998) 978-985
46. Kowalczykowski S.C. Cancer: catalyst of a catalyst. Nature 433 (2005) 591-592
47. Tannenbaum B., Mofunanya T., and Schoenfeld A.R. DNA damage repair is unaffected by mimicked heterozygous levels of BRCA2 in HT-29 cells. Int J Biol Sci 3 (2007) 402-407
48. Warren M., Lord C.J., Masabanda J., Griffin D., and Ashworth A. Phenotypic effects of heterozygosity for a BRCA2 mutation. Hum Mol Genet 12 (2003) 2645-2656
49. Wiegant W.W., Overmeer R.M., Godthelp B.C., van Buul P.P., and Zdzienicka M.Z. Chinese hamster cell mutantV-C8 a model for analysis of Brca2 function. Mutat Res 600 (2006) 79-88
50. Yu D.S., Sonoda E., Takeda S., Huang C.L., Pellegrini L., Blundell T.L., and Venkitaraman A.R. Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2. Mol Cell 12 (2003) 1029-1041